Evidence profile
SLU-PP-332 (10 mg Vial)
SLU-PP-332 is a small-molecule research compound studied for estrogen-related receptor activity. The reviewed findings come from cells and animals.
01
Product identity
It is a small molecule, not a peptide.
Vial and capsule listings are different product forms and do not establish equivalent exposure.
The supplier heading reads “SLU-PP-332 | 10mg”, but a size field in its description says 5mg. The linked heading identifies this catalogue variant; the amount and formulation of supplied stock require confirmation before any quantity is used.[5]
02
What has been studied
Primary preclinical study
Muscle and exercise biology
- Population or model
- Cultured muscle cells and mice
- Study route or material
- Laboratory assays and mouse intraperitoneal administration
The original study linked ERR activity to muscle-cell metabolism and exercise-related findings in mice.[1]
Primary preclinical study
Metabolic models
- Population or model
- Mouse models of obesity and metabolic dysfunction
- Study route or material
- Intraperitoneal animal study
A later mouse study reported changes in energy use, adiposity and insulin sensitivity. These model-specific findings support further research, not a human treatment conclusion.[2]
03
Evidence limits
Human efficacy, safe exposure and an administration regimen are not established by these studies.
The published vehicle and experimental durations do not validate a generic BAC-water preparation or the previous multi-week vial plan.
The reviewed sources do not establish patient instructions for this product. No dose, cycle, preparation method or administration schedule is provided here.
04
Formulation and handling evidence
Exact product identity and strength.
Solubility, vehicle compatibility and stability for the intended laboratory method.
A compatible diluent, prepared-solution stability and container/device compatibility must be supported for the exact formulation. The diluent manufacturer’s instructions do not supply a universal storage period for every dissolved substance.[4]
05
Approval context
This profile has not established Canadian authorization of the linked research product.[3]
06
Sources and review scope
- SLU-PP-332 exercise-response studyPrimary preclinical study · Abstract; original published methods previously checked · Checked 2026-09-08
- SLU-PP-332 metabolic-syndrome studyPrimary preclinical study · Abstract; original published methods previously checked · Checked 2026-09-08
- Health Canada: unauthorized injectable peptide productsRegulatory advisory · Fresh Health Canada advisory read, including product/DIN and RUO-label limits · Checked 2026-09-09
- Hospira/Pfizer: bacteriostatic water manufacturer informationManufacturer information; US presentation · Fresh manufacturer page, relevant compatibility/storage/supply passages · Checked 2026-09-09
- Amino Labs: SLU-PP-332 | 10mgSupplier listing; identity reference · Exact heading, SKU, form and supplier URL from the full catalogue capture; not stock-lot authentication · Checked 2026-09-09
This is a selected-source evidence summary. It is not a systematic review, formal certainty grade or qualified clinical sign-off. Study dates and source-check dates are distinct.